ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells

Yutaka Torii, Rina Kato, Yukito Minami, Kiyoshi Hasegawa, Takuma Fujii, Yasuhiro Udagawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Backgroud/Aim: We previously demonstrated that high protein expression of excision repair crosscomplementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). Materials and Methods: Firstly, half-maximal (50%) inhibitory concentration (IC50) values for cisplatin or 5-FU were calculated in cervical adenocarcinoma, HCA-1, and TCO-2 cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) assay. ERCC1 mRNA and protein levels were investigated by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting. Secondly, cisplatinresistant HCA-1 cells, designated HCA-1R cells were established, and IC50 values for cisplatin and 5-FU were calculated by the MTT assay. ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. Results: HCA-1 and TCO-2 cells exhibited similar sensitivity to cisplatin, and 5-FU, and comparable expression of ERCC1 mRNA and protein levels. HCA-1R cells exhibited two-fold higher resistance to cisplatin and a significantly higher level of ERCC1 mRNA expression compared to native HCA-1 cells. ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. Conclusion: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalAnticancer Research
Volume34
Issue number1
Publication statusPublished - 01-01-2014

Fingerprint

DNA Repair
Cisplatin
Adenocarcinoma
Fluorouracil
Inhibitory Concentration 50
Messenger RNA
Reverse Transcription
Cell Line
Polymerase Chain Reaction
Proteins
Chemoradiotherapy
Therapeutics
Disease-Free Survival
Western Blotting
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Torii, Y., Kato, R., Minami, Y., Hasegawa, K., Fujii, T., & Udagawa, Y. (2014). ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. Anticancer Research, 34(1), 107-115.
Torii, Yutaka ; Kato, Rina ; Minami, Yukito ; Hasegawa, Kiyoshi ; Fujii, Takuma ; Udagawa, Yasuhiro. / ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. In: Anticancer Research. 2014 ; Vol. 34, No. 1. pp. 107-115.
@article{8b70476b979b4b25a733367d684d585a,
title = "ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells",
abstract = "Backgroud/Aim: We previously demonstrated that high protein expression of excision repair crosscomplementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). Materials and Methods: Firstly, half-maximal (50{\%}) inhibitory concentration (IC50) values for cisplatin or 5-FU were calculated in cervical adenocarcinoma, HCA-1, and TCO-2 cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) assay. ERCC1 mRNA and protein levels were investigated by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting. Secondly, cisplatinresistant HCA-1 cells, designated HCA-1R cells were established, and IC50 values for cisplatin and 5-FU were calculated by the MTT assay. ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. Results: HCA-1 and TCO-2 cells exhibited similar sensitivity to cisplatin, and 5-FU, and comparable expression of ERCC1 mRNA and protein levels. HCA-1R cells exhibited two-fold higher resistance to cisplatin and a significantly higher level of ERCC1 mRNA expression compared to native HCA-1 cells. ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. Conclusion: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma.",
author = "Yutaka Torii and Rina Kato and Yukito Minami and Kiyoshi Hasegawa and Takuma Fujii and Yasuhiro Udagawa",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "107--115",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

Torii, Y, Kato, R, Minami, Y, Hasegawa, K, Fujii, T & Udagawa, Y 2014, 'ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells', Anticancer Research, vol. 34, no. 1, pp. 107-115.

ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. / Torii, Yutaka; Kato, Rina; Minami, Yukito; Hasegawa, Kiyoshi; Fujii, Takuma; Udagawa, Yasuhiro.

In: Anticancer Research, Vol. 34, No. 1, 01.01.2014, p. 107-115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells

AU - Torii, Yutaka

AU - Kato, Rina

AU - Minami, Yukito

AU - Hasegawa, Kiyoshi

AU - Fujii, Takuma

AU - Udagawa, Yasuhiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Backgroud/Aim: We previously demonstrated that high protein expression of excision repair crosscomplementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). Materials and Methods: Firstly, half-maximal (50%) inhibitory concentration (IC50) values for cisplatin or 5-FU were calculated in cervical adenocarcinoma, HCA-1, and TCO-2 cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) assay. ERCC1 mRNA and protein levels were investigated by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting. Secondly, cisplatinresistant HCA-1 cells, designated HCA-1R cells were established, and IC50 values for cisplatin and 5-FU were calculated by the MTT assay. ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. Results: HCA-1 and TCO-2 cells exhibited similar sensitivity to cisplatin, and 5-FU, and comparable expression of ERCC1 mRNA and protein levels. HCA-1R cells exhibited two-fold higher resistance to cisplatin and a significantly higher level of ERCC1 mRNA expression compared to native HCA-1 cells. ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. Conclusion: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma.

AB - Backgroud/Aim: We previously demonstrated that high protein expression of excision repair crosscomplementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). Materials and Methods: Firstly, half-maximal (50%) inhibitory concentration (IC50) values for cisplatin or 5-FU were calculated in cervical adenocarcinoma, HCA-1, and TCO-2 cell lines by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) assay. ERCC1 mRNA and protein levels were investigated by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting. Secondly, cisplatinresistant HCA-1 cells, designated HCA-1R cells were established, and IC50 values for cisplatin and 5-FU were calculated by the MTT assay. ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. Results: HCA-1 and TCO-2 cells exhibited similar sensitivity to cisplatin, and 5-FU, and comparable expression of ERCC1 mRNA and protein levels. HCA-1R cells exhibited two-fold higher resistance to cisplatin and a significantly higher level of ERCC1 mRNA expression compared to native HCA-1 cells. ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. Conclusion: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84897024778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897024778&partnerID=8YFLogxK

M3 - Article

C2 - 24403450

AN - SCOPUS:84897024778

VL - 34

SP - 107

EP - 115

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -

Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T, Udagawa Y. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. Anticancer Research. 2014 Jan 1;34(1):107-115.